

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB	3235-
Number:	0104
Estimated average	je
burden hours per	
response	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)							
1. Name and Address of Reporting	2. Date of Eve	ent Requiring	3. Issuer Nan	ne and Ticker	or Trac	ling Symbol	
Person [*]	Statement		Syros Pharmaceuticals, Inc. [SYRS]			SYRS]	
Flagship Ventures Fund IV, L.P.	(Month/Day/Y)	(ear)					
(Last) (First) (Middle)	06/29/2016		4. Relationsh	ip of Reporting	g	5. If Amendment, Date Original	
1 MEMORIAL DRIVE #7			Person(s) to I			Filed(Month/Day/Year)	
(Street)			(Check all applicab Director X 10 ⁶			6. Individual or Joint/Group	
CAMBRIDGE, MA 02142			Officer (gi		specify	Filing(Check Applicable Line) Form filed by One Reporting Person X_Form filed by More than One Reporting Person	
(City) (State) (Zip)		Table I - N	on-Derivati	ve Securitie	es Ben	eficially Owned	
1.Title of Security		2. Amount of	Securities	3.	4. Nat	ure of Indirect Beneficial	
(Instr. 4)		Beneficially (Owned	Ownership	Owne	rship	
		(Instr. 4)		Form: Direct	(Instr.	5)	
				(D) or			
				Indirect (I) (Instr. 5)			
				(Illsu. 5)			
Common Stock		213,332		Ι	See F	Footnote (5)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exe and Expirati (Month/Day/Ye	rcisable on Date	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
Series A-1 Preferred Stock	<u>(1)</u>	(1)	Common Stock	213,333 <u>(6)</u>	\$ <u>(1)</u>	Ι	See Footnote (6)	
Series A-1 Preferred Stock	<u>(1)</u>	<u>(1)</u>	Common Stock	53,333 <mark>(7)</mark>	\$ <u>(1)</u>	Ι	See Footnote (7)	
Series A-2 Preferred Stock	<u>(2)</u>	<u>(2)</u>	Common Stock	1,066,666 <u>(6)</u>	\$ <u>(2)</u>	Ι	See Footnote (6)	
Series A-2 Preferred Stock	<u>(2)</u>	<u>(2)</u>	Common Stock	266,666 (7)	\$ <u>(2)</u>	Ι	See Footnote (7)	
Series A-3 Preferred Stock	<u>(3)</u>	<u>(3)</u>	Common Stock	1,600,000 <u>(6)</u>	\$ <u>(3)</u>	Ι	See Footnote (6)	
Series A-3 Preferred Stock	<u>(3)</u>	<u>(3)</u>	Common Stock	400,000 (7)	\$ <u>(3)</u>	Ι	See Footnote (7)	
Series B Preferred Stock	<u>(4)</u>	<u>(4)</u>	Common Stock	474,661 <u>(6)</u>	\$ <u>(4)</u>	Ι	See Footnote (6)	
Series B Preferred Stock	<u>(4)</u>	<u>(4)</u>	Common Stock	118,665 <u>(7)</u>	\$ <u>(4)</u>	Ι	See Footnote (7)	

Reporting Owners

Reporting Owner Name / Address		Relationships					
		10% Owner	Officer	Other			
Flagship Ventures Fund IV, L.P. 1 MEMORIAL DRIVE #7 CAMBRIDGE, MA 02142		Х					
Flagship Ventures Fund IV-Rx, L.P. 1 MEMORIAL DRIVE #7 CAMBRIDGE, MA 02142		Х					
Flagship VentureLabs IV, LLC 1 MEMORIAL DRIVE #7 CAMBRIDGE, MA 02142		Х					
Flagship Ventures Fund IV General Partner LLC 1 MEMORIAL DRIVE #7 CAMBRIDGE, MA 02142		Х					
AFEYAN NOUBAR 1 MEMORIAL DRIVE #7 CAMBRIDGE, MA 02142		Х					
KANIA EDWIN M JR 1 MEMORIAL DRIVE #7 CAMBRIDGE, MA 02142		Х					

Signatures

FLAGSHIP VENTURES FUND IV, L.P. By: Flagship Ventures Fund IV General Partner LLC	
By:/s/ Noubar Afeyan Name: Noubar B. Afeyan, Ph.D. Title: Manager	06/29/2016
**Signature of Reporting Person	Date
FLAGSHIP VENTURES FUND IV-RX, L.P. By: Flagship Ventures Fund IV General Partner LLC By: /s/ Noubar Afeyan Name: Noubar B. Afeyan, Ph.D. Title: Manager	06/29/2016
Signature of Reporting Person	Date
FLAGSHIP VENTURELABS IV, LLC By: Flagship Ventures Fund IV, L.P. By: Flagship Ventures Fund IV General Partner LLC By: /s/ Noubar Afeyan Name: Noubar B. Afeyan, Ph.D. Title: Manager	06/29/2016
Signature of Reporting Person	Date
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC By: /s/ Noubar Afeyan Name: Noubar B. Afeyan, Ph.D. Title: Manager	06/29/2016
**Signature of Reporting Person	Date
/s/ Noubar Afeyan NOUBAR B. AFEYAN, PH.D.	06/29/2016
	06/29/2016 Date
/s/ Noubar Afeyan NOUBAR B. AFEYAN, PH.D.	

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Series A-1 Preferred Stock is convertible into Common Stock on a 3.75-for-one basis into the number of shares shown in column 3 (1) at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further

consideration. The shares have no expiration date.
The Series A-2 Preferred Stock is convertible into Common Stock on a 3.75-for-one basis into the number of shares shown in column 3
(2) at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

The Series A-3 Preferred Stock is convertible into Common Stock on a 3.75-for-one basis into the number of shares shown in column 3(3) at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

The Series B Preferred Stock is convertible into Common Stock on a 3.75-for-one basis into the number of shares shown in column 3 at(4) any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Ventures Fund IV, L.P. ("Flagship IV") is the manager of VentureLabs IV. Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV, Flagship IV LLC and each of these

(5) individuals may be deemed to share voting and investment power with respect to all shares held by VentureLabs IV. Each of the filing persons other than VentureLabs IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a limited partner of Flagship IV and a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the extent of his pecuniary interest therein.

Held by Flagship IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the

(6) with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a limited partner of Flagship IV and a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all charge hald by Flagship IV LLC and each of the filing persons other than

(7) deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons other than Flagship IV-Rx disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.